Brief: Bioage Labs Announces Company Updates On APJ, NLRP3, And Platform Programs
28/01/2025 14:07
Jan 28 (Reuters) - BIOAGE Labs Inc BIOA.O :
* BIOAGE LABS ANNOUNCES COMPANY UPDATES ON APJ, NLRP3, AND
PLATFORM PROGRAMS
* BIOAGE LABS: NOMINATION OF NLRP3 INHIBITOR BGE-102 AS A
DEVELOPMENT CANDIDATE, WITH INITIAL PH1 CLINICAL DATA
ANTICIPATED BY END OF 2025
Source text: ID:nGNX4tHV5V
Further company coverage: BIOA.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP